Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04368702 · ClinicalTrials.gov registry record · NA
CONFIRM: Magnetic Resonance Guided Radiation Therapy
A NA study of Bladder Cancer and Gastric Cancer, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT04368702 is a NA study of Bladder Cancer and Gastric Cancer that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 70 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04368702, a NA study of Bladder Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.
Conditions Studied
Interventions
- RADIATION Viewray MRIdian® Linac
Study Locations (2)
Massachusetts
- Brigham & Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-05-01 |
| Est. Completion | 2029-06-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04368702
The ClinicalTrials.gov registry entry for NCT04368702 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Viewray MRIdian® Linac is the first listed.
NCT04368702 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04368702 about?
NCT04368702 is a clinical study titled "CONFIRM: Magnetic Resonance Guided Radiation Therapy". This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.
What is the current status of trial NCT04368702?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2021-05-01. Estimated completion is 2029-06-18.
What conditions does trial NCT04368702 study?
This clinical trial studies the following conditions: Bladder Cancer, Gastric Cancer, Mantle Cell Lymphoma, Invasive Breast Cancer, Larynx Cancer.
What interventions are being tested in trial NCT04368702?
The interventions under investigation include: Viewray MRIdian® Linac (RADIATION).
Who is sponsoring clinical trial NCT04368702?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04368702 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
RECRUITING · NA
-
Bladder Cancer Screening Trial
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.